Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) EBIT (2023 - 2025)

Historic EBIT for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$52.6 million.

  • Zenas BioPharma's EBIT fell 2829.4% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.7 million, marking a year-over-year decrease of 5085.05%. This contributed to the annual value of -$163.9 million for FY2024, which is 34118.77% down from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's EBIT is -$52.6 million, which was down 2829.4% from -$55.2 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's EBIT ranged from a high of $35.6 million in Q3 2023 and a low of -$55.6 million during Q4 2024
  • In the last 3 years, Zenas BioPharma's EBIT had a median value of -$39.7 million in 2024 and averaged -$33.1 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 21504.6% in 2024, then tumbled by 2829.4% in 2025.
  • Over the past 3 years, Zenas BioPharma's EBIT (Quarter) stood at -$24.8 million in 2023, then crashed by 124.48% to -$55.6 million in 2024, then rose by 5.47% to -$52.6 million in 2025.
  • Its EBIT was -$52.6 million in Q3 2025, compared to -$55.2 million in Q2 2025 and -$37.3 million in Q1 2025.